首页> 美国卫生研究院文献>Springer Open Choice >Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized Controlled Trial
【2h】

Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized Controlled Trial

机译:在口服抗糖尿病药控制不佳的超重和肥胖中国2型糖尿病患者中高甘露糖胰岛素相对于标准开始剂量的安全性和有效性:一项随机对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTreatment with basal insulin in Chinese populations is currently sub-optimal, with delayed initiation of insulin treatment and inadequate dose titration. Increasing the initial dose of insulin may be a practicable and effective solution to the problem of titration. A higher initial dose will be helpful for patients to achieve the blood glucose target and improve treatment satisfaction and compliance as well require fewer steps to titrate. Considering that overweight and obese patients usually require higher insulin doses because of insulin resistance, a higher initial dose of the basal insulin is feasible in overweight and obese patients with type 2 diabetes. However, safety is an important issue needing to be considered for higher initial dose treatment. The aim of this study is to assess the safety and efficacy of higher (0.3 U/kg) compared with standard (0.2 U/kg) starting doses of basal insulin in overweight and obese Chinese patients with type 2 diabetes who have failed to achieve glycaemic control using oral antidiabetic drugs (OADs).
机译:背景技术目前,在中国人群中用基础胰岛素治疗尚不理想,胰岛素治疗开始时间延迟且剂量滴定不足。增加胰岛素的初始剂量可能是解决滴定问题的切实可行的解决方案。较高的初始剂量将有助于患者达到血糖目标并提高治疗满意度和依从性,并且所需的滴定步骤更少。考虑到超重和肥胖患者通常由于胰岛素抵抗而需要更高的胰岛素剂量,因此对于超重和肥胖的2型糖尿病患者,较高的基础胰岛素初始剂量是可行的。但是,安全性是较高初始剂量治疗需要考虑的重要问题。这项研究的目的是评估在体重过重和肥胖的中国2型糖尿病患者中,较高的(0.3U / kg)与标准的起始剂量(0.2U / kg)相比基础胰岛素的安全性和有效性使用口服降糖药(OAD)进行控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号